Frontier IP Group (FIPP)

Sector:

Support

Index:

FTSE AIM All-Share

 41.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 60.00p
  • 52 Week Low: 33.00p
  • Currency: UK Pounds
  • Shares Issued: 56.17m
  • Volume: 31,971
  • Market Cap: £23.31m

Frontier IP incorporates new firm in Portugal

By Josh White

Date: Tuesday 12 Feb 2019

LONDON (ShareCast) - (Sharecast News) - University intellectual property commercialisation specialist Frontier IP announced "strong progress" in Portugal on Tuesday, with the incorporation of a new company which would be called 'Insignals Neurotech'.
The AIM-traded firm said Insignals was developing patented technology to aid deep-brain stimulation surgery on patients suffering Parkinson's disease, epilepsy and other neural conditions.

Frontier IP would hold a 33% stake in the company, which would be its third spin-out in Portugal, where it aimed to be a leader in university IP commercialisation.

Insignals - a spin out from the Portuguese Institute for Systems and Computer Engineering, Technology and Science (INESC TEC) with the support of University of Porto's São João University Hospital - was developing wireless wearable devices to precisely measure wrist rigidity to help surgeons place brain implants more accurately.

The first product was aimed at Parkinson's disease, and had already undergone two clinical studies.

Increased muscle rigidity was described as one of the key symptoms of the disease, and was often treated by implanting deep brain stimulation electrodes when drugs no longer had an effect.

Frontier IP said Insignals' devices could help place the implants more accurately.

It said doctors evaluated wrist rigidity during surgery to decide the optimum position for the implant.

Currently, that was performed by two trained surgeons making a judgement by manually manipulating the wrist, which meant evaluation could be biased by the physicians' experience and perception.

Other systems designed to provide objective and quantitative evaluation were said to be "complicated" to set up, and were impractical for use during surgical procedures, with Insignals' device easier to set up and use.

Potential applications included helping pharmaceutical companies monitor or assess the impact of new or approved drugs in rigidity reduction during clinical trials as well.

Frontier IP said Insignals had already received interest from potential industry partners, and was looking to enter into collaboration agreements to extend clinical trials in Portugal, the UK and Germany.

It was established to commercialise the work of João Paulo Cunha, associate professor with Agregação at the Department of Electrical and Computer Engineering at the Faculty of Engineering of the University of Porto, and senior researcher at the INESC TEC Institute for Systems and Computer Engineering.

There, he created the Biomedical Research And INnovation (BRAIN) research group and co-founded the Centre for Biomedical Engineering Research.

"The creation of the Insignals Neurotech startup with our partners from Frontier IP will provide a strong innovation vehicle to consolidate the neuro-technology we've been developing for several years at INESC TEC and University of Porto, and take it a step further to the international market," said João Paulo Cunha.

Frontier IP chief executive officer Neil Crabb added that the company was "delighted" to welcome Insignals to the group.

"The company's technology has the potential to improve the accuracy of where to place an implant and relieve the symptoms of Parkinson's disease and other neural conditions," Crabb explained.

"The spin-out provides further evidence that we are now gaining serious traction in Portugal, a country with a lot of exciting intellectual property and few companies providing commercialisation services."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

FIPP Market Data

Currency UK Pounds
Share Price 41.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 60.00p
52 Week Low 33.00p
Volume 31,971
Shares Issued 56.17m
Market Cap £23.31m

FIPP Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
35.58% above the market average35.58% above the market average35.58% above the market average35.58% above the market average35.58% above the market average
53.33% above the sector average53.33% above the sector average53.33% above the sector average53.33% above the sector average53.33% above the sector average
Price Trend
55.99% below the market average55.99% below the market average55.99% below the market average55.99% below the market average55.99% below the market average
77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average
Income Not Available
Growth
93.43% above the market average93.43% above the market average93.43% above the market average93.43% above the market average93.43% above the market average
93.94% above the sector average93.94% above the sector average93.94% above the sector average93.94% above the sector average93.94% above the sector average

FIPP Dividends

No dividends found

Trades for 21-May-2024

Time Volume / Share Price
13:29 1,344 @ 40.54p
11:36 2,893 @ 41.47p
11:02 6,510 @ 41.47p
08:51 150 @ 43.00p
08:51 3 @ 43.00p

FIPP Key Personnel

CEO Neil Crabb
CFO Jo Stent

Top of Page